Quarterly ResultMay 15, 2026, 09:17 AM
CervoMed Q1 Net Loss Widens to $7.96M; Going Concern Doubt
AI Summary
CervoMed Inc. reported a significantly wider net loss of $7.96 million for Q1 2026, compared to a $4.89 million net loss in Q1 2025. The company also disclosed substantial doubt about its ability to continue as a going concern, as its $12.9 million in cash, cash equivalents, and marketable securities are insufficient to fund operations for the next twelve months. Grant revenue ceased in Q1 2026, contributing to increased operating losses and cash burn.
Key Highlights
- Net loss widened to $7.96 million in Q1 2026 from $4.89 million in Q1 2025.
- Net loss per share increased to $(0.86) in Q1 2026 from $(0.56) in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $12.9 million as of March 31, 2026.
- Accumulated deficit reached $105.7 million as of March 31, 2026.
- Grant revenue was $0 in Q1 2026, down from $1.92 million in Q1 2025.
- Total operating expenses increased to $8.11 million in Q1 2026 from $7.22 million in Q1 2025.
- Net cash used in operating activities was $8.02 million in Q1 2026, up from $3.89 million in Q1 2025.
Price Impact
More from CRVO